The Indian Biotech Leader Expands its Operations in the U.S. Strategically Through the Launch of a New Biosimilar
The Indian Biotech Leader Expands its Operations in the U.S. Strategically Through the Launch of a New Biosimilar

The Indian Biotech Leader Expands its Operations in the U.S. Strategically Through the Launch of a New Biosimilar

Over the past year, Biocon delivered a return of 15.51 per cent, while its three-year return stood at -9.75 per cent.

DSIJ Intelligence-2 Article rating: 5.0

Over the past year, Biocon delivered a return of 15.51 per cent, while its three-year return stood at -9.75 per cent.

Peer Company of Ola Electric, Revolt Motors, Begins Operations in Nepal with First Dealership in Kathmandu
Peer Company of Ola Electric, Revolt Motors, Begins Operations in Nepal with First Dealership in Kathmandu

Peer Company of Ola Electric, Revolt Motors, Begins Operations in Nepal with First Dealership in Kathmandu

The stock has delivered a remarkable 2,000 per cent multibagger return in 5 years. Investors should monitor this Small-Cap company closely.

DSIJ Intelligence-2 Article rating: 5.0

The stock has delivered a remarkable 2,000 per cent multibagger return in 5 years. Investors should monitor this Small-Cap company closely.

2,000 Per cent Returns: Poonawala Backed NBFC Launches Gold Loan Business
2,000 Per cent Returns: Poonawala Backed NBFC Launches Gold Loan Business

2,000 Per cent Returns: Poonawala Backed NBFC Launches Gold Loan Business

In the last one year the stock price has given negative 23 per cent return while in 5 years it has given multibagger returns of 2,040 per cent.

DSIJ Intelligence-2 Article rating: 5.0

In the last one year the stock price has given negative 23 per cent return while in 5 years it has given multibagger returns of 2,040 per cent.

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg.

DSIJ Intelligence-1 Article rating: 5.0

The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.

Medical Equipment & Supplies Expands Global Reach in Medical Devices; Secures USFDA Registration
Medical Equipment & Supplies Expands Global Reach in Medical Devices; Secures USFDA Registration

Medical Equipment & Supplies Expands Global Reach in Medical Devices; Secures USFDA Registration

Company's products are available both online, through its proprietary store and major e-commerce platforms, and offline, with a presence in over 22,000 retail touchpoints across 460+ towns in India.

DSIJ Intelligence-1 Article rating: 5.0

The company's wholly-owned subsidiary, Nureca Technologies Pvt Ltd, specializes in manufacturing medical devices with an annual capacity of 8 lakh units.

RSS
1345678910Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR